DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

J. P B O'Connor; A. Jackson; G. J M Parker; G. C. Jayson

doi:10.1038/sj.bjc.6603515

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

J. P B O'Connor, A. Jackson, G. J M Parker, G. C. Jayson

Research output: Contribution to journal › Article › peer-review

Abstract

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T1-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date. © 2007 Cancer Research UK.

Original language	English
Pages (from-to)	189-195
Number of pages	6
Journal	British Journal of Cancer
Volume	96
Issue number	2
DOIs	https://doi.org/10.1038/sj.bjc.6603515
Publication status	Published - 29 Jan 2007

Keywords

Angiogenesis inhibitors
Biomarkers
Clinical trials
Dynamic contrast-enhanced magnetic resonance imaging
Image analysis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6603515

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17211479

Cite this

@article{68e5e8509aef4ccbb928a81d12312092,

title = "DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents",

abstract = "Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T1-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date. {\textcopyright} 2007 Cancer Research UK.",

keywords = "Angiogenesis inhibitors, Biomarkers, Clinical trials, Dynamic contrast-enhanced magnetic resonance imaging, Image analysis",

author = "O'Connor, {J. P B} and A. Jackson and Parker, {G. J M} and Jayson, {G. C.}",

year = "2007",

month = jan,

day = "29",

doi = "10.1038/sj.bjc.6603515",

language = "English",

volume = "96",

pages = "189--195",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "2",

}

TY - JOUR

T1 - DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

AU - O'Connor, J. P B

AU - Jackson, A.

AU - Parker, G. J M

AU - Jayson, G. C.

PY - 2007/1/29

Y1 - 2007/1/29

N2 - Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T1-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date. © 2007 Cancer Research UK.

AB - Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T1-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date. © 2007 Cancer Research UK.

KW - Angiogenesis inhibitors

KW - Biomarkers

KW - Clinical trials

KW - Dynamic contrast-enhanced magnetic resonance imaging

KW - Image analysis

U2 - 10.1038/sj.bjc.6603515

DO - 10.1038/sj.bjc.6603515

M3 - Article

SN - 0007-0920

VL - 96

SP - 189

EP - 195

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 2

ER -

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this